Clinically Validated Probiotics
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised
Electronic Logs - The next phase of execution maturity in pharma
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Complex Journey from Innovation to Patient impact
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Designing and Developing Green Drug Delivery Systems
Scientist, University of Kansas
Dr Sagar Salave is a Scientist at the University of Kansas USA specializing in mRNALNP therapeutics and viral vaccine formulation With a background in major pharmaceutical MNCs including Lupin and Ciron Drugs he possesses extensive expertise in drug discovery and nanotechnologydriven RD He serves as an Associate Editor for Applied Biochemistry and Biotechnology Journal Springer and sits on the Ed...
Articles
Pharma Regulatory Bottlenecks and Vaccination Delays
The world is grappling with the inefficiencies that have plagued the healthcare system since covid has wreaked havoc The unprecedented loss of human lives could have been prevented if vaccine diplomacy was robust and supported by more affluent nations Half of the inefficiencies and disparities that plague the healthcare and pharma sector
Research Insights
Model Based on COVID-19 Evidence to Predict and Improve Pandemic Control
The COVID pandemic has dramatically affected all of humanity but it also provided an enormous amount of data which may provide valuable lessons on how to effectively face future events of similar characteristics
Case Studies
Prescribing Antibiotics to ‘At-Risk’ Children With Influenza-Like Illness In Primary Care: A Qualitative Case Study
Abstract Objectives National Institute for Health and Care Excellence guidelines recommend immediate antibiotic treatment of respiratory tract infections in atrisk individuals with comorbidities Observational evidence suggests that influenza particularly predisposes children to bacterial comp
Techno Trends
Arrowhead Pharmaceuticals Develops Novel Plozasiran
Arrowhead Pharmaceuticals has developed plozasiran formerly AROAPOC a novel investigational therapy designed to reduce triglycerides in adults with familial chylomicronemia syndrome FCS
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Kinase Inhibitors as Antiviral Agents
Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.
Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.
Artificial Intelligence - A current and future tool to learn chemical sciences
Ruchi Bharti received her M.Sc. from Patna University, in organic chemistry. PhD from National Institute of Technology Patna (NIT Patna), in 2012. There she worked on the development of new organocatalysts and their utilization in the synthesis of diverse heterocyclic compounds via multimulticomponent reactions. In 2017, she enrolled as assistant professor at R. P Sharma Institute of Technology, Since 2018, she joined Department of Chemistry, University Institute of Sciences, Chandigarh University, Punjab as Assistant Professor. Her recent research work is focused on the functionalisation of diverse heterocycles, multicomponent reactions, organocatalysis and their related biological and medicinal applications.
Advancing Automation and Digitalization in the Industrial Microbiology Workflow
Brad is Head of Biomonitoring Strategic Initiatives, which includes development and execution of the Digital strategy in Robotics & Automation, eBusiness, Informatics and the Biomonitoring Ecosystem. Throughout his 10 years at the company, Brad has been engaged in Commercial, Operation and Strategy with regional and global focus.
Machine Learning for New Drugs
Sneha Rai completed her Ph.D. from Computational and Structural Biology Lab., Department of Biological Sciences and Engineering at Netaji Subhas Institute of Technology (DU). She did masters in Bioinformatics from Banaras Hindu University and holds six years of bioinformatics research experience. Her area of interest includes structural bioinformatics, systems biology, protein/gene network analysis, data mining, computer aided drug designing, computational genomics, NGS data analysis, variant analysis and their clinical interpretation.
Venugopal Bhatia graduated from NSIT in 2019 with a B.E. in Biotechnology. During his undergraduate studies he was involved as an undergraduate researcher at the Computational and Structural Biology Laboratory and worked on two projects which were later published in Nature Scientific Reports and Elsevier Computational Biology and Chemistry. After a brief stint in industry, he's now pursuing his Master's at Yale.
Sonika Bhatnagar, Ph.D. (Biophysics), AIIMS works in the broad area of computational molecular biology. Her laboratory uses techniques of drug target selection, drug design & discovery, machine learning, and integrative genomics & proteomics towards Cardiovascular disease drug design and infectious disease therapeutics.
Government Investment in AI Capabilities will Cement Singapore’s Position as a Premier Clinical Trial Location
Edwin Ng joined Medidata in 2014 and heads the Life Science industry of Dassault Systemes across the Asia Pacific region. Under his leadership, the company’s regional business recorded significant year-on-year growth and achieved multiple leadership awards. Edwin has spent the last 27 years of his career managing enterprise solutions businesses.
press releasesRead more...
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies
Kos Biotechnology Partners Kos a global life sciences investment firm bridging the US and European biopharma ecosystems today announced a strategic investment in Golden Age Health GAH through its inaugural fund Kos BioVentures As part of this partnership Alex Tzoukas Managing Partner and CoFounder
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
Merck a leading science and technology company today announced a collaboration with NVIDIA Corporation Santa Clara California USA Microsoft Corporation Redmond Washington USA and Dawn Health AS Copenhagen Denmark to build an innovative model for Patient Support Programs PSPs The fourway collaboratio...
EventsRead more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials
AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
